帕曲妥單抗
化合物
帕曲妥單抗（INN：Patritumab）是一種人單株抗體，設計用於治療非小細胞肺癌。它充當免疫調節劑。[1][2]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | HER3 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1262787-83-6 |
| ChemSpider |
|
| UNII | |
| KEGG | |
臨床試驗
它正在進行針對頭頸部鱗狀細胞癌的二期臨床試驗。[3]
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 (PDF). WHO Drug Information. 2011, 25 (4) [2024-01-24]. （原始內容存檔 (PDF)於2016-03-04）.
- ^ Horinouchi H. The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy. December 2016, 16 (12): 1549–1555. PMID 27744717. S2CID 4035336. doi:10.1080/14712598.2016.1249846.
- ^ Clinical trial number NCT02633800 for "A Clinical Trial Using Patritumab or Placebo in Combination With Cetuximab and a Platinum Agent for Patients With Squamous Cell Cancer of the Head and Neck" at ClinicalTrials.gov
- ^ Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer. October 2016 [2024-01-24]. （原始內容存檔於2024-01-24）.